Immuno-Oncology Resource Center
Immuno-Oncology Resource Center
April 30, 2018
1 min read
Save

FDA grants priority review to cemiplimab for advanced cutaneous squamous cell carcinoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA granted priority review to cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma or those with locally advanced disease who are not candidates for surgery.

The FDA previously granted breakthrough therapy designation to cemiplimab (REGN2810; Regeneron, Sanofi), an investigational human monoclonal antibody that targets PD-1.

The FDA based the priority review designation on data from the phase 2 single-arm, open-label EMPOWER-CSCC 1 trial, as well as data from two phase 1 expansion cohorts. In those trials, researchers enrolled patients with metastatic cutaneous squamous cell carcinoma and patients with locally advanced disease who were not candidates for surgery.

In the EMPOWER-CSCC 1 trial, researchers reported an independent review-assessed overall response rate of 46.3% among 82 cemiplimab-treated patients.

The safety profile appeared consistent with other approved anti-PD-1 therapies.

Researchers will present results from these trials at the ASCO Annual Meeting, scheduled for June 1-5 in Chicago.

The FDA set an action date of Oct. 28.